FDA granted Orphan Drug Designation to Debio 1143 for the treatment of ovarian cancer. Debio 1143 is an oral, small molecule inhibitor with a dual pro-apoptotic and immunomodulatory mode of action developed as a chemo/radio-sensitizer, according to Debiopharm International SA, the drug’s sponsor. Debiopharm plans to expand the clinical development of this therapy to patients...
Bits of good news for NIH flickered consistently over the past week.
